Physician profile
Mark Barr
NPI 1962473371
$2,759.80
in general payments reported to CMS, 2019-2025
30 companies · $14.71 in 2025
The $14.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $322 · 2021: $530 · 2022: $418 · 2023: $611 · 2024: $18.79 · 2025: $14.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.00 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $486.41 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $279.04 | 2019-2023 | Fasenra |
| Lilly USA, LLC | $268.93 | 2019-2023 | Mounjaro, Trulicity |
| Amgen INC. | $244.78 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.39 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $78.88 | 2019-2022 | |
| Pfizer INC. | $78.75 | 2019-2023 | |
| Allergan, INC. | $73.54 | 2020 | |
| Merck Sharp & Dohme LLC | $57.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $46.89 | 2019-2023 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $35.59 | 2019-2021 | |
| Inspire Medical Systems, INC. | $33.50 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $26.55 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $24.50 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $24.18 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $23.49 | 2023 | Optimizer |
| Alexion Pharmaceuticals, INC. | $19.41 | 2021 | |
| Astellas Pharma US INC | $16.59 | 2019 | |
| Abbott Laboratories | $16.19 | 2022 | |
| Edwards Lifesciences Corporation | $15.69 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.89 | 2023 | Seglentis |
| Grifols USA, LLC | $12.42 | 2021 | |
| Eisai INC. | $11.89 | 2020 | |
| Genentech USA, INC. | $11.66 | 2019 | |
| Clarus Therapeutics INC. | $7.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.